Please check your internet connection and try again.
# Potassium Chloride
## Overview
Potassium chloride (KCl) is an essential electrolyte and mineral. It is crucial for nerve impulse conduction, muscle contraction, and maintaining acid-base balance. Available in oral and intravenous formulations.
## Primary Indications
* Treatment and prevention of hypokalemia.
* Potassium supplementation in patients receiving diuretics that deplete potassium.
## Adult Dosing
**Oral:**
* **Hypokalemia:** Typically 20-60 mEq per day, divided into 1-4 doses. Some sources suggest up to 100 mEq per day in severe cases, but this requires careful monitoring.
* **Maintenance:** 10-40 mEq per day.
* Maximum single oral dose: Generally no defined maximum, but larger doses increase risk of gastrointestinal (GI) adverse effects. Doses >20 mEq at one time should be given with caution and ideally divided.
**Intravenous (IV):**
* **Treatment of Hypokalemia:**
* **Mild to Moderate:** 10-20 mEq/hour.
* **Severe/Symptomatic:** Up to 40 mEq/hour, but requires continuous cardiac monitoring and frequent serum potassium checks.
* **Maximum IV infusion rate:** Generally 20 mEq/hour for peripheral lines, and up to 40 mEq/hour for central lines. Higher rates should only be used in emergencies with continuous cardiac monitoring.
* **Maximum IV concentration:** Peripheral lines: Typically limited to 40 mEq/L. Central lines: Can be higher, up to 80-100 mEq/L, but this depends on local protocols and the specific clinical situation.
* **Maximum total IV dose:** Generally no absolute maximum, guided by serum potassium levels and clinical response.
*Note: Exact dosing, infusion rates, and concentrations for IV KCl are highly protocol-dependent and should be guided by local institutional guidelines and the patient's specific clinical status.*
## Pediatric Dosing
* **Oral:**
* **Hypokalemia:** 1-5 mEq/kg/day, divided into 1-4 doses.
* **Maintenance:** 1 mEq/kg/day.
* Maximum daily dose: Typically up to 3 mEq/kg/day or 200 mEq/day, whichever is less.
* **Intravenous (IV):**
* **Hypokalemia:** Typically 0.3-1 mEq/kg/dose, infused over 1-3 hours. Higher doses (up to 3 mEq/kg/dose) may be used in life-threatening situations, with extreme caution and continuous cardiac monitoring.
* **Maximum IV infusion rate:** 0.5-1 mEq/kg/hour, not to exceed 20 mEq/hour in neonates.
* **Maximum IV concentration:** Generally 30-40 mEq/L for peripheral administration; higher concentrations may be used centrally if needed.
*Note: Pediatric dosing requires careful calculation and consideration of the specific formulation and route of administration.*
## Dose Adjustments
* **Renal Impairment:** Dosage reduction is necessary. Potassium is renally excreted; severe renal impairment can lead to hyperkalemia. Monitor serum potassium closely.
* **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes as liver disease can sometimes affect fluid and electrolyte balance.
## Contraindications
* Severe renal impairment.
* Conditions that predispose to hyperkalemia, such as Addison's disease, untreated Addison's disease, acute dehydration, significant tissue breakdown (e.g., severe burns, crush injuries), or certain medications (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics) in patients with compromised renal function.
* Hyperkalemia.
* Known hypersensitivity to the drug.
* Gastrointestinal obstruction or delayed gastric emptying (for extended-release oral formulations).
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal discomfort, flatulence.
* **Serious:** Hyperkalemia (can be life-threatening, symptoms include muscle weakness, paresthesias, arrhythmias, cardiac arrest), esophageal or gastric ulceration and perforation (especially with undissolved tablets or rapid infusion).
## Key Drug Interactions
* **ACE Inhibitors, ARBs, Potassium-Sparing Diuretics (e.g., spironolactone, amiloride), Trimethoprim, NSAIDs:** Increased risk of hyperkalemia.
* **Potassium-Binding Resins (e.g., sodium polystyrene sulfonate):** May reduce absorption of resins.
* **Cholinergic Agents:** May increase the risk of GI toxicity.
* **Digitalis Glycosides:** Hypokalemia may increase the risk of digitalis toxicity; hyperkalemia can decrease it.
## Monitoring
* **Serum Potassium:** Essential, especially with IV administration, in patients with renal impairment, or when risk factors for hyperkalemia are present. Frequency depends on clinical status, dose, and route.
* **Renal Function (BUN, Creatinine):** To assess risk of potassium accumulation.
* **ECG:** In cases of severe hypokalemia or suspected hyperkalemia, or during rapid IV potassium repletion.
* **Signs and Symptoms:** Monitor for symptoms of hypokalemia (weakness, fatigue, cramps) or hyperkalemia (muscle weakness, paresthesias, arrhythmias).
* **Fluid and Electrolyte Balance:** Monitor other electrolytes as clinically indicated.
## Clinical Pearls
* Oral potassium chloride tablets (especially extended-release formulations) can cause significant GI irritation, ulceration, or perforation. Patients should be advised to take them with food and a full glass of water and to report any severe abdominal pain, black stools, or vomiting immediately.
* IV potassium administration is painful and must be diluted and infused slowly. Extravasation can cause tissue damage.
* Correcting potassium levels too rapidly can be dangerous.
* Always use the lowest effective dose to correct potassium deficits and prevent recurrence.
* Consider the total daily potassium intake from all sources (diet, IV fluids, medications).
***
**Disclaimer:** This information is intended for clinical use and does not replace professional medical judgment. Always consult the most current prescribing information, institutional protocols, and patient-specific factors before making treatment decisions.
